Sanofi eyeing Brazil generics firm?

23 February 2009

French drug major Sanofi-Aventis is in talks to acquire Brazilian generics producer Medley SA at a cost of some 500.0 million reals  ($220.0 million), reports the local newspaper Valor Economico, although  confirmation of any negotiations has not been available from either  party. However, such an acquisition would be in line with the French  company's growth strategy, as recently discussed by its new chief  executive, Chris Viehbacher (Markettetter February 16).

Medley produces mainly generic and over-the-counter medicines and is  sixth in Brazil's pharmaceutical league or third in the list of  domestically-owned companies. The firm is represented in 15 Latin  American countries and, more recently, has been trying to break into the  European market. Growth has come mainly from the export of finished and  semi-finished drugs. Sales of the Sao Paulo-based enterprise are put at  some 275.0 million euros ($351.9 million) a year. One factor seen to be  favoring a rapid conclusion to a deal is that local Brazilian generics  producers are finding access to fresh financing difficult in the current  economic climate.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight